4219-55-0

Usage

Uses

Used in Pharmaceutical Industry:
4-Propanoylbenzoic acid is used as a precursor in the production of nonsteroidal anti-inflammatory drugs (NSAIDs) and other pharmaceuticals for its ability to inhibit the cyclooxygenase (COX) enzyme.
Used in Dye and Fragrance Industry:
4-Propanoylbenzoic acid is used as a building block in the production of dyes, fragrances, and other organic chemicals.
Used in Material Science:
4-Propanoylbenzoic acid has potential applications in the field of material science, although specific uses are not detailed in the provided materials.
Safety Precautions:
4-Propanoylbenzoic acid poses certain health hazards, and safety precautions should be taken when handling it.

InChI:InChI=1/C10H10O3/c1-2-9(11)7-3-5-8(6-4-7)10(12)13/h3-6H,2H2,1H3,(H,12,13)

Upstream product

• 120-61-6 1,4-benzenedicarboxylic acid dimethyl ester 
• 554-12-1 propanoic acid methyl ester 
• 619-58-9 4-iodobenzoic acid 
• 201230-82-2 carbon monoxide 
• 96-10-6 diethylaluminium chloride 
• 52129-98-3 4-propionylbenzonitrile 
• 1004992-92-0 1-(4-(hydroxymethyl)phenyl)propan-1-ol 
• 10342-83-3 4'-Bromopropiophenone 
• 352233-12-6 1-[4-(hydroxymethyl)phenyl]propan-1-one 

Downstream Products

• 17745-40-3 methyl p-propanoylbenzoate 
• 153929-32-9 p-Propionylbenzoyl Chloride 
• 170846-89-6 (RS)-α-ethyl-4-carboxyphenylglycine 
• 142721-20-8 methyl 4-<2-(2,4-diamino-6-pteridinyl)-1-ethylethenyl>benzoate 
• 66952-47-4 1-<4-(2-Thienylcarbonyl)phenyl>-1-propanone 
• 860344-53-2 4-propionylbenzoic acid benzyl ester 
• 1204698-80-5 (E)-4-oxo-4-phenylbut-2-enyl 4-propionylbenzoate 
• 860344-87-2 ethyl 4-propionylbenzoate 
• 651042-69-2 ethyl 4-(2-amino-1,3-thiazol-4-yl)benzoate 
• 920009-75-2 ethyl 4-(2-bromopropanoyl)benzoate 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools

The most common CF mutation, F508del, impairs the processing and gating of CFTR protein. This deletion results in the improper folding of the protein and its degradation before it reaches the plasma membrane of epithelial cells. Present correctors, like VX809 only induce a partial rescue of the mutant protein. Our previous studies reported a class of compounds, called aminoarylthiazoles (AATs), featuring an interesting activity as correctors. Some of them show additive effect with VX809 indicating a different mechanism of action. In an attempt to construct more interesting molecules, it was thought to generate chemically hybrid compounds, blending a portion of VX809 merged to the thiazole scaffold. This approach was guided by the development of QSAR analyses, which were performed based on the F508del correctors so far disclosed in the literature. This strategy was aimed at exploring the key requirements turning in the corrector ability of the collected derivatives and allowed us to derive a predictive model guiding for the synthesis of novel hybrids as promising correctors. The new molecules were tested in functional and biochemical assays on bronchial CFBE41o-cells expressing F508del-CFTR showing a promising corrector activity.

PROTEASE INHIBITORS

Compounds of the formula II: wherein R1 and R2 are independently H, F or CH3; or R1 forms an ethynyl bond and R2 is H or C3-C6 cycloalkyl which is optionally substituted with one

PROTEASE INHIBITORS

Compounds of the formula II, wherein R3 is C1-C3 alkyl or C3-C6 cycloalkyl, either of which is optionally substituted with one or two methyl and/or a fluoro, trifluoromethyl or methoxy, when R3/

Cysteine Protease Inhibitors

Compounds of the formula II: wherein R2 is the side chain of leucine, isoleucine, cyclohexylglycine, O-methyl threonine, 4-fluoroleucine or 3-methoxyvaline; R3 is H, methyl or F; Rq is trifluoromethyl and Rq′ is H or Rq and Rq′ define keto; Q is a p-(C1-C6alkylsulphonyl)phenyl- or an optionally substituted 4-(C1-C6alkyl)piperazin-1-yl-thiazol-4-yl- moiety have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.

PROTEASE INHIBITORS

Compounds of the formula (II): wherein R2 is the side chain of leucine, isoleucine, cyclohexylglycine, O-methyl threonine, 4-fluoroleucine or 3-methoxyvaline; R3 is H, methyl or fluoro; R4 is C1-C6alkyl; E is a bond or thiazolyl, optionally substituted with methyl or fluoro; n is 0 or 1; or a pharmaceutically acceptable salt, N-oxide or hydrate thereof; have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsinK, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.

CuCl catalyzed selective oxidation of primary alcohols to carboxylic acids with tert-butyl hydroperoxide at room temperature

Direct oxidation of primary alcohols to the corresponding carboxylic acids is performed highly efficiently at room temperature with anhydrous tert-butyl hydroperoxide in the presence of a catalytic amount of easily available CuCl under ligand free conditions in acetonitrile. Benzylic alcohols are more reactive than aliphatic alcohols, and these benzylic alcohols are selectively oxidized to the corresponding acids in the presence of aliphatic alcohols such as 1-octanol and 1-decanol.

Synthesis of some tolperisone metabolites in racemic and optically active form

1-(4′-Carboxyphenyl)-2-methyl-3-(piperidine-1-yl)-propan-1-one M3, erythro-1-(4′-carboxyphenyl)-2-methyl-3-(piperidine-1-yl)-propan-1-ol M4 and threo-1-(4′-carboxyphenyl)-2-methyl-3-(piperidine-1-yl)-propan-1-ol M5, metabolites of the muscle relaxant tolp

Analogues of the potent nonpolyglutamatable antifolate N(α)-(4-amino-4- deoxypteroyl)-N(δ)-hemiphthaloyl-L-ornithine (PT523) with modifications in the side chain, p-aminobenzoyl moiety, or 9,10-bridge: Synthesis and in vitro antitumor activity

Seven N(α)-(4-amino-4-deoxypteroyl)-N(δ)-hemiphthaloyl-L-ornithine (2, PT523) analogues were synthesized by modifications of the literature synthesis of the corresponding AMT (1) analogues and were tested as inhibitors of tumor cell growth. In growth assa

Easy and General Method for the Preparation of m- and p-Acylbenzoic Acids: A New Synthesis of rac-Suprofen

A method for the preparation of m- and p-acylbenzoic acids 3 based on the Claisen condensation of isophthalic or terephthalic diesters 1 with α-methylenecarboxylic esters 2 is described. p-Propionylbenzoic acid p-4 (R=Me) is used in a new synthesis of rac-suprofen (11). Key Words: Acylbenzoic acids / Claisen condensation / rac-Suprofen / Thalium(III) nitrate

CARBONYLATIVE CROSS-COUPLING REACTION OF ARYL IODIDES WITH ALKYLALUMINUMS BY PALLADIUM COMPLEX CATALYSIS

Secondary and/or tertiary alcohols and unsymmetrical ketones have been obtained in moderate to good yields by palladium-catalyzed (5 molpercent) carbonylative coupling of aryl iodides with alkylaluminum compounds under very mild conditions (20-50 deg C, 1 atm of carbon monoxide).The type of th reaction product depended on the aluminum reagent employed.While the selective formation of secondary alcohols was observed in the reaction with i-Bu3Al, the use of Et3Al led to a mixture of a ketone and two alcoholic products.With Et2AlCl predominantly unsymmetrical ketones were produced.In all cases, formation of directly cross-coupled products was not observed.DME and benzene can be used as solvents, but THF is unsuitable.Nickel catalysts were found to be ineffective for this reaction.